CIBC Bancorp USA’s Spyre Therapeutics SYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$723K Buy
8,118
+3,996
+97% +$384K ﹤0.01% 1199
2026
Q2
$366K Buy
+4,122
New +$301K ﹤0.01% 1442

Other funds holding SYRE

CIBC Bancorp USA's SYRE Position: Q3 2026 in Review

CIBC Bancorp USA increased its Spyre Therapeutics (SYRE) stake by 97% in Q3 2026, buying an estimated $384K and bringing the position to 8,118 shares worth $723K. The position accounts for ﹤0.01% of the portfolio, ranked #1199.

CIBC Bancorp USA first reported a position in SYRE in Q2 2026 and has held it in 2 quarters since. 286 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • CIBC Bancorp USA held 8,118 shares of Spyre Therapeutics worth $723K as of Q3 2026.
  • CIBC Bancorp USA bought 3,996 Spyre Therapeutics shares in Q3 2026, an estimated $384K.
  • Spyre Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1199 holding.
  • CIBC Bancorp USA first reported a position in Spyre Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 286 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.